-
Top Trending Tickers On StockTwits For February 14
Friday, February 14, 2014 - 12:06pm | 902Read More...Here's a look at the top tickers trending on StockTwits.com Tesla: Robust sales in California According to Bloomberg, Tesla Motors' (NASDAQ: TSLA) Model S sedan ranks third place among luxury cars in California in 2013. According to a market report from the California New Car Dealers...
-
Tug Of War In Ariad Pharmaceuticals
Tuesday, January 28, 2014 - 3:36pm | 888Read More...When investing in the biotech and the pharmaceutical arena, there are always plenty of surprises. Following the announcement of drug trials by the FDA, there can be wild price fluctuations in an issue's price. Many of the smaller companies are also the targets of the big pharma that are looking...
-
Top Trending Tickers On StockTwits For January 17
Friday, January 17, 2014 - 11:17am | 637Read More...Here's a look at the top tickers trending on StockTwits.com. Ariad Pharmaceuticals On Friday morning, Ariad Pharmaceuticals (NASDAQ: ARIA) announced the commercial availability of Iclusig for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute...
-
Market Wrap For January 10: Job Growth Weak, But Unemployment Falls
Friday, January 10, 2014 - 5:53pm | 2337Read More...Major indices ended the day little changed as investors and traders were not sure how to react to today's job reports. 74,000 jobs were added, well below the estimated 196,000. The report proved to be a complete contradiction to every other report previously seen. Related: ETFs Moving On The...
-
Market Wrap For January 3: Bernanke Speaks As Fed Chairman For Last Time; Markets Little Moved
Friday, January 3, 2014 - 5:29pm | 1497Read More...Fed Chairman Ben Bernanke took to the podium today in what many consider to be his farewell speech. During his tenure, Bernanke developed the nickname "Helicopter Ben," which is likely to stick with him for some time. Bernanke noted, "The FOMC's decision to modestly reduce the pace of asset...
-
Geron Revealed Positive Imetelstat Results Amidst Data Concerns
Thursday, November 7, 2013 - 2:10pm | 253Read More...Geron (NASDAQ: GERN) revealed positive results from Imetelstat data this morning. Geron published that Imetelstat, a drug used to treat myelofibrosis, had an overall response rate of 44 percent. Further, the company wrote, “Among 13 patients with leukocytosis, 10 (77 percent) normalized their...
-
CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified
Wednesday, January 11, 2012 - 5:26pm | 64Read More...A previous story published on Benzinga.com (subsequently unpublished) referenced a tweet by Adam Feuerstein indicating his opinion that Alkermes' drug candidate Bydureon would be approved. Bydureon has not been approved. Neither Alkermes' CEO nor the FDA have made any statement indicating if the...
-
Update On Seattle Genetics FDA Meeting
Thursday, July 14, 2011 - 3:01pm | 66Read More...TheStreet.com's Adam Feuerstein is tweeting about the Seattle Genetics (NASDAQ: SGEN) FDA meeting. Feuerstein just tweeted that the FDA panel is moving to questions and voting on Adcetris in ALCL. The FDA voted 10-0 to recommend accelerated approval of Seattle Genetics' Adcetris. Shares have...
-
Vanda Pharmaceuticals Falling On Disappointing Drug Sales (VNDA)
Friday, February 4, 2011 - 1:21pm | 100Read More...According to Adam Feuerstein at theStreet.com, Vanda Pharmaceuticals' (NASDAQ: VNDA) first year sales of a schizophrenia drug Fanapt developed by VNDA and sold by Novartis (NYSE: NVS) totaled just $31.4 million, well below analysts' expectations. According to Feuerstein, that number is high...
-
Nobody Wants Savient Pharmaceuticals (SVNT)
Monday, October 25, 2010 - 11:03am | 74Read More...Shares of Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) were down sharply right before it was halted. During the halt, Savient announced that potential bidders have passed on the company, according to Adam Feuerstein and Bloomberg. Right before the halt, shares were down $1.65 to $20.05, a loss of 7...
-
Adam Feuerstein Thinks Merger May Be In Works In Biotech (CTIC, SNSS)
Wednesday, October 20, 2010 - 11:40am | 119Read More...Adam Feuerstein, senior biotech writer at the TheStreet.com, tweeted that he thinks that Cell Therapeutics, Inc. (NASDAQ: CTIC) may buy Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). This is all speculation on his part, and there has been no talk of a merger between the companies. Sunesis...
-
Spherix Down After Being Sharply Higher (SPEX)
Thursday, October 7, 2010 - 2:18pm | 83Read More...An update on Spherix Incorporated (NASDAQ: SPEX), which was sharply higher this morning on news that it completed a successful Phase 3 test for its diabetes drug. Well, it appears traders aren't buying it, as shares were up around 90% in pre-market trading, and are now down 18% in a dramatic...
-
Betting on Biotech - Interview with Adam Feuerstein, Senior Columnist and Biotech Analyst of TheStreet.com
Friday, October 1, 2010 - 12:46pm | 2331Read More...Hello and welcome to Zing Talk, where Benzinga brings you the biggest names and brightest minds from Silicon Valley to New York City. Direct Download Subscribe in iTunes Today our guest is Adam Feuerstein, Senior Columnist and Biotech analyst for TheStreet.com. How ya doing today Adam? Good...
-
Sequenom Files $150 Million Shelf Offering
Tuesday, September 21, 2010 - 5:31pm | 65Read More...According to a tweet from TheStreet.com's senior biotech writer Adam Feuerstein, Sequenom, Inc. (NASDAQ: SQNM) has filed a $150 million shelf offering. Shares are down in after-hours trading on this news, losing nearly 3% to trade at $6.85. SQNM had finished the regular session at $7.05, good for a...
-
Strong Response To Live Blog On Arena (ARNA)
Thursday, September 16, 2010 - 3:34pm | 90Read More...TheStreet.com's senior biotech columnist Adam Feuerstein had a live blog today, in which he discussed the Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) ruling from the FDA on its weight loss drug, lorcaserin. The blog had more 5,000 readers, and almost 350,000 page views, an unprecedented number of...
